HFpEF vs. HFrEF: How To Improve Heart Failure Drug Development
XTalks
APRIL 15, 2021
Dr. Benoit Tyl, MD, FESC, medical and scientific director, cardiology at Servier, says that the disconnect between correlation and causality in cardiovascular disease trials is partially responsible for the lack of approved HFpEF therapies. Figure 1: The use of Mendelian randomization to validate genetic drug targets.
Let's personalize your content